AtriCure announced today that it launched its new CryoSphere+ cryoablation probe for the CryoIce platform. CryoSphere+ leverages new insulation technology, reducing freeze times by 25% compared to the legacy CryoSphere device. The original CryoIce device first received FDA clearance in November 2018 and aided in more than 60,000 procedures to date. The CryoSphere+ device picked […]
atricure
AtriCure grows sales by 21% in Q4
AtriCure shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast. Shares of ATRC fell 2.8% at $33.25 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.7%. The Mason, Ohio-based company posted losses of $9.8 million. That […]
AtriCure management expects Street-beating Q4 sales
AtriCure today announced preliminary fourth-quarter revenue results that beat the expectations of Wall Street analysts. The Mason, Ohio–based developer of surgical tools for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management expects to report Q4 2023 revenue of $106.5 million, up 21% year-over-year. The consensus on The Street was $102.43 million. […]
AtriCure adds J&J veteran to its board
AtriCure (Nasdaq:ATRC) announced today that it appointed longtime Johnson & Johnson executive Shlomi Nachman to its board of directors. Nachman most recently served as company group chair within the Johnson & Johnson Medical Devices (now MedTech) business. He also joined the board of transcatheter aortic valve replacement technology developer JenaValve in September. “I am thrilled […]
Are investors overreacting on AtriCure after Medtronic’s Penditure launch?
BTIG analysts say a small survey of surgeons may indicate an oversell of AtriCure stock following Medtronic’s launch of a competing device. Medtronic this week launched the Penditure left atrial appendage (LAA) exclusion device, adding another system to a competitive space. AtriCure, Abbott and Boston Scientific all offer LAA devices, while Johnson & Johnson MedTech […]
AtriCure raises guidance on Street-beating Q2 as stock ticks up
AtriCure (Nasdaq:ATRC) shares rose today on second-quarter financial results that came in ahead of the consensus forecast. Shares of ATRC ticked up 5.2% at $55.94 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — increased slightly. The Mason, Ohio-based cardiovascular care company posted […]
AtriCure stock rises on Street-beating Q1
AtriCure (Nasdaq:ATRC) shares are trending upward today on first-quarter results that beat the consensus forecast. Shares of ATRC ticked up 6.2% at $42.65 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.2%. The Mason, Ohio-based cardiovascular care company posted losses of […]
The medtech companies potentially affected by Silicon Valley Bank’s closure
U.S. banking regulators’ latest moves may provide some reassurance for medtech and other companies exposed to Silicon Valley Bank‘s closure. The California Department of Financial Protection and Innovation shuttered SVB on March 10 to stave off what was turning into an old-fashioned bank run. Silicon Valley Bank has been a huge name in the tech […]
AtriCure treats first patient in stroke prevention trial
AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its left atrial appendage exclusion for stroke prevention (LeAAPS) trial. U.S. co-principal investigator Dr. Marc Gerdisch treated the first patient at Franciscan St. Francis Heart Center in Indianapolis. The prospective, randomized, blinded investigational device exemption (IDE) trial will evaluate the safety and effectiveness of […]
AtriCure beats The Street in Q3
AtriCure (Nasdaq:ATRC) shares were unchanged after hours today on third-quarter results that topped the consensus forecast. The Mason, Ohio-based cardiac ablation device company posted losses of $12.3 million. That amounts to 27¢ per share on sales of $83.2 million for the three months ended Sept. 30, 2022. AtriCure reported a massive bottom-line slide into the […]
Analysts high on AtriCure following Converge AFib procedure update
Analysts have a positive outlook on AtriCure (Nasdaq:ATRC) following an investor webinar discussing the company’s Convergent procedure. Convergent uses the company’s EPi-Sense system. Its epicardial-sensing electrodes allow both electrophysiologists (EPs) and cardiothoracic surgeons to sense and record cardiac signals. It can be used for the coagulation of cardiac tissue using radiofrequency (RF) energy. According to […]